NCT01406873View on ClinicalTrials.gov

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2017

Study Completion Date

March 31, 2017

Conditions
Myotonic Dystrophy
Interventions
DRUG

Mexiletine

150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months

DRUG

Placebo

150 mg/kg placebo capsules taken by mouth, three times daily for 6 months

Trial Locations (1)

14642

University of Rochester Medical Center, Department of Neurology, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT01406873 - Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 | Biotech Hunter | Biotech Hunter